Functional Brands Issues Letter to Shareholders
Lake Oswego, Oregon--(Newsfile Corp. - November 24, 2025) - Functional Brands Inc. (NASDAQ: MEHA), a leading innovator in wellness and performance products, issued the following letter from Eric Gripentrog, Chief Executive Officer. Dear Valued Shareholders, It is with great pride and enthusiasm that I write to you at this pivotal moment for our company. As the CEO of Functional Brands, I want to share our story, reaffirm our vision and values, and set the tone for the next chapter
Household / Consumer / Cosmetics, Health
2025-11-24 8:00 AM EST | Functional Brands Inc.
NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates
Expanded CONNECT SCI Study data demonstrated unprecedented durable improvement in function, independence, and quality of life in individuals living with chronic spinal cord injury Completed a U.S. Food and Drug Administration (FDA) Type C meeting in September; FDA confirmed that multiple regulatory routes are available to support approval of NVG-291 as the first pharmacologic treatment for spinal cord injury Completed a US$1
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-24 7:05 AM EST | NervGen Pharma Corp.
NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury
Week 16 follow-up data, coupled with blinded exit interviews conducted up to 364 days after the study period, confirm durable and wide-ranging upper and lower-body improvements compared to placebo Participant-reported outcomes highlight substantial improvements in bladder control and muscle spasticity compared to placebo Statistically significant reduction of hyperactive reticulospinal signaling in upper and lower limbs
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-24 7:00 AM EST | NervGen Pharma Corp.
Cheelcare Receives "Compliant" Rating from Health Canada Following Routine Inspection
Markham, Ontario--(Newsfile Corp. - November 24, 2025) - Cheelcare Inc. (TSXV: CHER) ("Cheelcare" or the "Company"), a Canadian leader in assistive mobility devices, has received a "Compliant" rating from Health Canada, following a routine regulatory inspection conducted between October 22 and November 3, 2025. The inspection was conducted at Cheelcare's new 16,000 sq. ft. manufacturing and R&D facility in Markham, which the Company began occupying this fall as part of its broader
2025-11-24 7:00 AM EST | Cheelcare Inc.
Skye Bioscience to Participate in Upcoming Investment Conferences
San Diego, California--(Newsfile Corp. - November 24, 2025) - Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will participate in the following upcoming investment conferences: Citi Global Healthcare Conference (Miami) 1x1 meetings: Dec. 2 Evercore Annual Healthcare Conference (Coral Gables) Fireside Chat: Dec. 3, 12:55 pm
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-11-24 7:00 AM EST | Skye Bioscience, Inc.
Defence Therapeutics Announces Convertible Debenture Conversion
Montreal, Quebec--(Newsfile Corp. - November 21, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation antibody-drug conjugate ("ADC"), announces that the holders of the Corporation's 8% convertible debentures issued on November 16, 2024 (the "Debentures") have converted all of the principal amount and the accrued interests thereof into an aggregate number of 2,607,600 common
Biotechnology, Pharmaceuticals, Health
2025-11-21 6:03 PM EST | Defence Therapeutics Inc.
FendX Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - November 21, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing technology-based solutions to reduce the spread of harmful pathogens, is pleased to announce it intends to settle outstanding debts totalling approximately $25,560 owed by the Company to two arms-length consultants for services performed and payable in common share
Technology, Healthcare and Hospitals, Health
2025-11-21 6:00 PM EST | FendX Technologies Inc.
Mobile-health Network Solutions Signs MOU to Secure Two Malaysian AI Data Center Projects; Facilities Intended to Power Expansion of Company's AI Digital Health Platform
Singapore, Singapore--(Newsfile Corp. - November 21, 2025) - Mobile-health Network Solutions (NASDAQ: MNDR) ("MNDR" or the "Company"), a leading AI HealthTech platform, today announced the signing of a legally binding Memorandum of Understanding (MOU) with PPG PP GRID SDN. BHD. ("PPG") for the acquisition of PPG project companies that own and are developing two high-density AI-optimized data centers in Sarawak, Malaysia. The data centers include a 25MW facility tar
2025-11-21 8:30 AM EST | Mobile-health Network Solutions
Edison Issues Report on Mendus (IMMU)
London, United Kingdom--(Newsfile Corp. - November 21, 2025) - Edison issues report on Mendus (OMX: IMMU). We have updated our investment view on Mendus following its expanded strategy for vididencel to chronic myeloid leukaemia (CML) and a broader acute myeloid leukaemia (AML) population, including chemo-eligible and chemo-ineligible patients, regardless of their measurable residual disease (MRD) status. In our view, this is a bold strategic pivot for a programme nearing Phase III read
Banking / Financial Services, Computer Hardware, Computer Software, Health
2025-11-21 4:50 AM EST | Edison Group
LevelJump Sets Date for Requisitioned Shareholder Meeting
Toronto, Ontario--(Newsfile Corp. - November 20, 2025) - Further to its news release of November 7, 2025, LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company") announces that its board of directors (the "Board") has called an annual and special meeting of shareholders (the "Meeting") to be held on May 26th, 2026 in response to a shareholder requisition (the "Requisition") submitted by Frank Teti and Franmar Properties Ltd. (collectively the "Concerned Shareholders"
Healthcare and Hospitals, Health
2025-11-20 4:15 PM EST | LevelJump Healthcare Corp.
PreveCeutical Provides Clarification of News Release Announcing Update on Plan of Arrangement with BioGene Therapeutics Inc.
Vancouver, British Columbia--(Newsfile Corp. - November 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, further to its news release of earlier today, the Company wishes to clarify that shareholders of record of November 24, 2025 will be issued new common shares of PreveCeutical and 0.02 of one share of BioGene Therapeutics Inc. About PreveCeutical PreveCeutical is a heal
Biotechnology, Pharmaceuticals, Health
2025-11-20 12:26 PM EST | PreveCeutical Medical Inc.
St. Baldrick's Foundation Awards Nearly $1.2 Million in Grants, Advancing Research and Hope for Kids with Cancer
Los Angeles, California--(Newsfile Corp. - November 20, 2025) - The St. Baldrick's Foundation, the largest charity funder of childhood cancer research grants in the U.S., is proud to announce nearly $1.2 million in new grants, continuing its mission to support research that brings safer, more effective treatments to kids with cancer. This latest round of funding includes nearly $1 million in Infrastructure Grants designed t
2025-11-20 12:00 PM EST | St. Baldrick's Foundation
Dr. William R. Shankle to Advance ACP-01 as a Treatment for Vascular Dementia
Calgary, Alberta--(Newsfile Corp. - November 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option patients suffering from pain, angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, is pleased to announce Dr. William R. Shankle, MS,
Biotechnology, Pharmaceuticals, Health
2025-11-20 9:00 AM EST | Hemostemix Inc.
Conexeu Sciences Signals a Major Breakthrough in 'Personalized Human Tissue Creation'
Reno, Nevada--(Newsfile Corp. - November 20, 2025) - Conexeu Sciences Inc. ("Conexeu" or the "Company"), a biotechnology innovator redefining regenerative medicine through a next-generation collagen-based platform, is pleased to announce that it has achieved a defining milestone in regenerative medicine with the first ever 3D-printed structures made entirely from its patented, functional extracellular matrix (ECM). Using its patented CXU™ platform, the Company has printed bovine-derived
Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-20 9:00 AM EST | Conexeu Sciences Inc.
Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares
Ontario and Chicago, Illinois--(Newsfile Corp. - November 20, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the Toronto Stock Exchange has accepted Medexus's notice of intention to make a normal course issuer bid, or NCIB, for its common shares (TSX: MDP). Under the NCIB, Medexus may purchase for cancellation up to 2,983,650 common shares, representing approximately 10% of the public float as defined under TSX rules. As of November 12, 2025, 32
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-20 7:30 AM EST | Medexus Pharmaceuticals Inc.
PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc.
Vancouver, British Columbia--(Newsfile Corp. - November 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, further to its News Releases of September 4, 2025, September 19, 2025, October 10, 2025 and October 20, 2025, the Company announces that it will be completing
Biotechnology, Pharmaceuticals, Health
2025-11-20 7:00 AM EST | PreveCeutical Medical Inc.
NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
Vancouver, British Columbia--(Newsfile Corp. - November 19, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that it has completed its previously announced non-brokered private placement (the "Non-Brokered Unit Offering") to certain institutional investors and other acc
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-19 4:26 PM EST | NervGen Pharma Corp.
ADIA Nutrition Inc. to Host Webinar on HSCT for MS and Autoimmune Conditions with HSCT Warriors
Winter Park, Florida--(Newsfile Corp. - November 19, 2025) - ADIA Nutrition, Inc. (OTCQB: ADIA) invites all shareholders, supporters, and potential investors to join a live webinar tomorrow, Thursday, November 20, 2025, at 6:30 PM EST, hosted by HSCT Warriors.
Healthcare and Hospitals, Health
2025-11-19 9:30 AM EST | Adia Nutrition Inc.
Edison Issues Report on Tradedoubler (TRAD)
London, United Kingdom--(Newsfile Corp. - November 19, 2025) - Edison issues report on Tradedoubler (OMX: TRAD). Tradedoubler has a strong proposition in performance marketing, with particular strengths in the partner (affiliate) and influencer areas. With the springboard of a leading position in Europe, it is now expanding operations into the US, the largest global advertising market. Its influencer marketing business, Metapic, is well-placed to take advantage of this dynamic and fast-
Banking / Financial Services, Computer Hardware, Computer Software, Health
2025-11-19 8:48 AM EST | Edison Group
Rock Salt Marketing Launches AI SEO Services for LLM Search Visibility
Salt Lake City, Utah--(Newsfile Corp. - November 19, 2025) - Award-winning Utah- and Nashville-based digital marketing agency, Rock Salt Marketing Cooperative, has officially launched its new AI SEO services as an add-on to its traditional SEO program, designed to help businesses nationwide improve visibility and performance across large language models (LLMs).
Real Estate, Travel, Health, Legal
2025-11-19 7:50 AM EST | Rock Salt Marketing Cooperative